Pregnancy-associated plasma protein A (PAPP-A) may be a viable therapeutic for targeting Ewing sarcoma in pediatric patients, a group of investigators suggested at the 2016 annual meeting of the American Association for Cancer Research.
The team pointed out that the five-year overall survival for pediatric patients with relapsed or metastatic Ewing sarcoma is less than 20%, indicating a clear need for novel targeted therapies.
“PAPP-A was identified as one of the top five